Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Cell entry of a host-targeting protein of oomycetes requires gp96.

Trusch F, Loebach L, Wawra S, Durward E, Wuensch A, Iberahim NA, de Bruijn I, MacKenzie K, Willems A, Toloczko A, Diéguez-Uribeondo J, Rasmussen T, Schrader T, Bayer P, Secombes CJ, van West P.

Nat Commun. 2018 Jun 14;9(1):2347. doi: 10.1038/s41467-018-04796-3.

2.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

3.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

4.

Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.

Toloczko A, Guo F, Yuen HF, Wen Q, Wood SA, Ong YS, Chan PY, Shaik AA, Gunaratne J, Dunne MJ, Hong W, Chan SW.

Cancer Res. 2017 Sep 15;77(18):4921-4933. doi: 10.1158/0008-5472.CAN-16-3413. Epub 2017 Jul 18.

5.

MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells.

Liu CY, Chan SW, Guo F, Toloczko A, Cui L, Hong W.

Oncotarget. 2016 Mar 22;7(12):13706-16. doi: 10.18632/oncotarget.7333.

6.

Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.

Ehrhardt H, Häcker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A, Debatin KM, Fulda S, Jeremias I.

Oncogene. 2008 Jan 31;27(6):783-93. Epub 2007 Jul 16.

PMID:
17637740
7.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.

Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, Debatin KM, Jeremias I.

Cancer Res. 2005 Sep 1;65(17):7888-95.

8.

Clinical genetic services for familial breast cancer in Poland.

Gronwald J, Menkiszak J, Huzarski T, Byrski T, Jakubowska A, Zajàczek S, Toloczko A, Podolski J, Górecka B, Zdziebkowska H, Stanislawski P, Stawicka M, Lubinski J.

Dis Markers. 1999 Oct;15(1-3):46. No abstract available.

9.

Hereditary breast cancer.

Gronwald J, Menkiszak J, Tołoczko A, Zajaczek S, Kładny J, Kurzawski G, Krzystolik K, Podolski J, Lubiński J.

Pol J Pathol. 1998;49(2):59-66. No abstract available.

PMID:
9798408
10.

Losses at 3p common deletion sites in subtypes of kidney tumours: histopathological correlations.

Hadaczek P, Podolski J, Toloczko A, Kurzawski G, Sikorski A, Rabbitts P, Huebner K, Lubinski J.

Virchows Arch. 1996 Sep;429(1):37-42.

PMID:
8865851
11.

Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas.

Druck T, Kastury K, Hadaczek P, Podolski J, Toloczko A, Sikorski A, Ohta M, LaForgia S, Lasota J, McCue P, et al.

Cancer Res. 1995 Nov 15;55(22):5348-53.

12.

Abnormalities of chromosome 5q correlate with morphologic features of better prognosis in clear cell renal carcinomas.

Podolski J, Huzarski T, Byrski T, Tołoczko A, Wrzecion S, Sikorski A, Mahoy P, Huebner K, Rabbitts P, Lubiński J.

Pol J Pathol. 1995;46(3):163-6.

PMID:
7496735
13.

Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas.

Lubinski J, Hadaczek P, Podolski J, Toloczko A, Sikorski A, McCue P, Druck T, Huebner K.

Cancer Res. 1994 Jul 15;54(14):3710-3.

Supplemental Content

Loading ...
Support Center